Abstract: Thermal conductive compositions, methods for their preparation, and use are provided, which include, for example, as thermal sinks, heat transfer systems, and other uses.

Abstract: A multi-arm polyethylene glycol derivative having a narrow molecular weight distribution represented by the formula (1): wherein, L represents a group selected from a linear or branched alkylene, arylene, or cycloalkylene group having two or more carbon atoms and combinations thereof, which may have an ether bond in a chain; X represents a dehydroxylation residue of a linear sugar alcohol having 5 or 7 carbon atoms; m is the number of polyethylene glycol chains bonded to X and represents 4 or 6; n is the average addition molar number of oxyethylene groups and represents an integer of 3 to 600; Y represents a single bond or an alkylene group as further defined herein; and Z represents a chemically reactive functional group.

Abstract: The compounds provided herein are phenyl analine amides and are useful for inhibiting histone deacteylase (“HDAC”) enzymes, such as HDAC1, HDAC2, and HDAC3.

Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

Abstract: The present invention relates primarily to a process for preparing certain phosphorus-containing cyanohydrins of the formula (I), and also to certain phosphorus-containing cyanohydrins per se and to their use for the preparation of glufosinate and/or glufosinate salts. The present invention further relates to certain mixtures particularly suitable for preparing the phosphorus-containing cyanohydrins of the formula (I).

Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.

Abstract: Novel iridium complexes containing a tetradentate or a hexadentate ligand, wherein a part of the ligand that is coordinated to iridium comprise an acetylacetonate structure. These complexes are useful as emitters for phosphorescent OLEDs.

Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Abstract: A method for producing a halohydantoin compound according to the present invention includes the steps of: (a) providing, in a dryer, a composition containing (i) at least one component selected from the group consisting of water, an organic solvent, and elemental halogen and (ii) a halohydantoin compound; and (b) drying the composition under reduced pressure in the dryer, the reduced pressure being reduced to a pressure lower than atmospheric pressure while introducing an inert gas from an outside source into the dryer.

Abstract: The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

Abstract: Methods of making and resultant acidulent/carbohydrate agglomerates. The acidulent may be citric acid having particle sizes ranging from about 1 micron to 20 microns agglomerated with a soluble carbohydrate co-agglomerate to formulate the various acidulent/carbohydrate agglomerates. In certain embodiments, the carbohydrate co-agglomerate may be maltodextrin to formulate citric acid/maltodextrin agglomerates. These citric acid/maltodextrin agglomerates are shelf stable when dry, have improved flowability, compressibility, mixability; dissolve easily and quickly in water; and provide an easy ready-to-use formulation that is suitable for use in compounding various food and pharmaceutical products.

Abstract: The present invention relates to processes for preparing for preparing 3-(methylsulfonyl)propionitrile. The processes comprise the steps of first reacting 2-chloroethyl methyl sulfide with sodium cyanide or potassium cyanide in a solvent or a solvent mixture to form 3-(methylthio)propionitrile, and then reacting the isolated 3-(methylthio)propionitrile with acetic anhydride, acetic acid, and hydrogen peroxide to form 3-(methylsulfonyl)propionitrile.

Abstract: Spirobifluroene compounds of the formula (1) which are suitable for use in electronic devices, and in particular organic electroluminescent devices, and to electronic devices that include the spirobifluorene compounds.

Abstract: A condensed cyclic compound is represented by Formula 1: where R1 to R12 are as defined in the specification and at least one of R1 to R12 is a group represented by Formula 2, and at least one of R1 to R12 is a group represented by Formula 3; where L1, L2, Ar1 to Ar4, a1 and a1 are as defined in the specification. An organic light-emitting device including the condensed cyclic compound.

Abstract: Provided herein are novel processes for preparing a compound of Formula (I) to the use of said compound as an intermediate in novel processes for the synthesis of indazole derivatives, and to indazole intermediates and derivatives prepared by the processes described herein.

Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.

Abstract: The claimed invention relates to the field of biologically active compounds and concerns 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an antiviral effect and is intended for the treatment and prophylaxis of human and animal viral diseases, primarily West Nile Virus, and can be used in the chemical and pharmaceutical industry, in scientific research laboratories and medical facilities, and also in veterinary science. The claimed invention is directed toward achieving the technical result of creating a novel effective drug of the azoloazine variety which exhibits antiviral activity toward a group of RNA-containing viruses, and reducing the dependence of the active compound on cell metabolism. This technical result is achieved in the creation of the novel drug 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an aniviral effect and has the formula (I).

Abstract: The present invention relates to a pharmaceutical composition and a cosmetic composition, which contain, as an active ingredient, a novel pseudo compound having similar structural characteristics to natural ceramide 1, or a pharmaceutically acceptable salt or solvate thereof, and the composition containing the compound of the present invention as an active ingredient has an excellent effect of enhancing a skin barrier function, thereby exhibiting an effect of alleviating inflammatory skin diseases, and has an excellent skin barrier improving function and an excellent skin moisturization enhancing effect.

Abstract: Disclosed are corrosion inhibitor compounds and compositions useful for preventing or inhibiting corrosion of surfaces found in cooling water applications. In some embodiments, the surfaces may include mild steel, aluminum, brass, copper, galvanized steel, a copper alloy, admirality brass, or any combination thereof. Also disclosed are methods of using the compounds and compositions as corrosion inhibitors. In some embodiments, the corrosion inhibitor compounds and compositions are used in cooling water applications.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.